EGFR
ENSG00000146648
Target class
Kinase
Chromosome
7
Approved drugs
21
Clinical candidates (approved and in development)
80
- Approved drugs
- 21
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 80
- Chemical probe available
- Yes
- Target name
- EGFR
- Gene name
- Epidermal growth factor receptor
- Gene symbol
- EGFR
- Previous gene symbols
- ERBB
- Protein name
- Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
- ERBB1
- ERRP
- Gene biotype
- Protein coding
- Gene family
- Erb-b2 receptor tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 78.34
- Tissue specificity (Gini)
- 0.474
- Tissue specificity (tau)
- 0.77
- KEGG gene identifiers
- hsa:1956
- Protein interaction confidence
- 0.845447
- Protein interaction partners
- 490
- R-HSA-1227986
- R-HSA-1236382
- R-HSA-1236394
- R-HSA-1250196
- R-HSA-1251932
- R-HSA-1257604
- R-HSA-177929
- R-HSA-179812
- R-HSA-180292
- R-HSA-180336
- R-HSA-182971
- R-HSA-1963640
- R-HSA-1963642
- R-HSA-212718
- R-HSA-2179392
- R-HSA-2219530
- R-HSA-445144
- R-HSA-5637810
- R-HSA-5638303
- R-HSA-5673001
- R-HSA-6785631
- R-HSA-6811558
- R-HSA-8847993
- R-HSA-8856825
- R-HSA-8856828
And 12 more, listed on the interactive page.
- End position
- 55211628
- Start position
- 55018820
- Chromosome
- 7
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Endoplasmic reticulum membrane
- Single-pass type I membrane protein. Golgi apparatus membrane
- Single-pass type I membrane protein. Nucleus membrane
- Single-pass type I membrane protein. Endosome . Endosome membrane. Nucleus . Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055). .
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
- Cell Junctions
- End piece
- Golgi apparatus
- Mid piece
- Plasma membrane
- Principal piece
- PubMed 17182860
- PubMed 20462955
- PubMed 23589287
- PubMed 26918609
- PubMed 27153536
- PubMed 2790960
- PubMed 35538033
- PubMed 17115032
- PubMed 17909029
- PubMed 20551055
- PubMed 20674546
- Tissue specificity (tau)
- 0.770495
- Expression inequality (Gini)
- 0.474198
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 78.34
- Skin - Not Sun Exposed (Suprapubic)
- 75.93
- Cells - Cultured fibroblasts
- 60.63
- Nerve - Tibial
- 43.12
- Vagina
- 40.6
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)78.34
- Skin - Not Sun Exposed (Suprapubic)75.93
- Cells - Cultured fibroblasts60.63
- Nerve - Tibial43.12
- Vagina40.6
- Adipose - Subcutaneous39.73
- Esophagus - Gastroesophageal Junction34.63
- Artery - Tibial33.2
- Breast - Mammary Tissue32.94
- Esophagus - Muscularis31.8
- Minor Salivary Gland31.63
- Cervix - Ectocervix30.95
- Esophagus - Mucosa29.91
- Fallopian Tube28.12
- Prostate27.05
- Adipose - Visceral (Omentum)25.84
- Thyroid25.04
- Cervix - Endocervix24.72
- Bladder23.53
- Artery - Aorta23.45
- Lung22.13
- Uterus21.4
- Ovary20.74
- Artery - Coronary20.18
- Colon - Sigmoid18.98
And 29 more, listed on the interactive page.
- GO:0001934
- GO:0007165
- GO:0007166
- GO:0007173
- GO:0008284
- GO:0030307
- GO:0030335
- GO:0033138
- GO:0034165
- GO:0038134
- GO:0042059
- GO:0042177
- GO:0042327
- GO:0043066
- GO:0043410
- GO:0043491
- GO:0045739
- GO:0045740
- GO:0045944
- GO:0050679
- GO:0050730
- GO:0051205
- GO:0051897
- GO:0070141
- GO:0070374
And 8 more, listed on the interactive page.
- GO:0005634
- GO:0005737
- GO:0005768
- GO:0005789
- GO:0005794
- GO:0005886
- GO:0005925
- GO:0009986
- GO:0010008
- GO:0016020
- GO:0016323
- GO:0030054
- GO:0030669
- GO:0031901
- GO:0032587
- GO:0032991
- GO:0043235
- GO:0045121
- GO:0048471
- GO:0097489
- GO:0097708
- GO:0003682
- GO:0004713
- GO:0004714
- GO:0004888
- GO:0005006
- GO:0005515
- GO:0019899
- GO:0019900
- GO:0019903
- GO:0030296
- GO:0031625
- GO:0042802
- GO:0045296
- GO:0051015
alopecia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351cardiomyopathy
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351Hepatotoxicity
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- liver
PubMed 38773351Skin rash
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- skin
PubMed 38773351diarrhoea
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- GI
PubMed 38773351epithelial inflammation
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351AST increase
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- liver
PubMed 38773351ocular keratitis
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- ocular
PubMed 38773351weight loss
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351interstitial lung disease
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- respiratory
PubMed 38773351heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Helps to maintain left ventricular function in setting of chronic catecholamine stimulation; mediates pro-survival signalling
Biological samples
- cardiovascular system
PubMed 21283106decreased appetite
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351ALT increase
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- liver
PubMed 38773351hypertension
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hEGFR, is one of one assay component(s) measured or calculated from the NVS_ENZ_hEGFR assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (4,080)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
- 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
- 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- 5G-EMERALD: Amivantamab in Malignant Brain Tumours
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
- A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
- A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
- A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Drugs (87)
- Abivertinib Epidermal growth factor receptor erbB1 inhibitor
- Abivertinib maleate Epidermal growth factor receptor erbB1 inhibitor
- AC-480 Epidermal growth factor receptor erbB1 inhibitor
- AEE-788 Epidermal growth factor receptor erbB1 inhibitor
- Afatinib Epidermal growth factor receptor erbB1 inhibitor
- Afatinib dimaleate Epidermal growth factor receptor erbB1 inhibitor
- Allitinib Epidermal growth factor receptor erbB1 inhibitor
- Amivantamab Epidermal growth factor receptor erbB1 inhibitor
- Aumolertinib Epidermal growth factor receptor erbB1 inhibitor
- AV-412 Epidermal growth factor receptor erbB1 inhibitor
- AV-412 FREE BASE Epidermal growth factor receptor erbB1 inhibitor
- AZD-3759 Epidermal growth factor receptor erbB1 inhibitor
- AZD-4769 Epidermal growth factor receptor erbB1 inhibitor
- Bafisontamab Epidermal growth factor receptor erbB1 inhibitor
- BMS-690514 Epidermal growth factor receptor erbB1 inhibitor
- Brigatinib Epidermal growth factor receptor erbB1 inhibitor
- Canertinib Epidermal growth factor receptor erbB1 inhibitor
- Canertinib dihydrochloride Epidermal growth factor receptor erbB1 inhibitor
- CEP-32496 Epidermal growth factor receptor erbB1 inhibitor
- Cetuximab Epidermal growth factor receptor erbB1 inhibitor